been well documented and reports of transcriptional repression during tumour progression are increasing. This review examines the role of posttranslational truncation of Ecadherin in cancer cells focusing on implications for tumour progression. The various proteins involved in the directed cleavage of E-cadherin and consequences of these truncations are discussed. 
Abbreviations used in this paper
E-cad 100 100-kDa E-cadherin fragment EMT epithelial-mesenchymal transition HAV histadine alanine valine HGF/SF hepatocyte growth factor/scatter factor MMP matrix metalloproteinase sE-cad soluble E-cadherin SL-1 stromelysin-1 cluding those that involve E-cadherin, occur to facilitate normal physiological processes such as morphogenesis, epithelial-mesenchymal transition (EMT) during organogenesis, cell division and apoptosis [Reinsch and Karsenti, 1994; Ivanov et al., 2001; Steinhusen et al., 2001; Zhu et al., 2001; Li et al., 2003; Shen and Kramer, 2004] . Disruption of cell-cell contacts and cell migration are key events in EMT and are increasingly linked with tumour progression, invasion and dissemination. While these may be critical to early stages of tumour progression, good evidence is emerging to indicate that re-expression of E-cadherin/re-epithelialization at the site of metastasis favours growth of the secondary tumour [see Chaffer et al., 2006, this volume] , suggesting a dynamic regulation throughout the metastasis process. Improved understanding of underlying mechanisms would contribute to identification of prognostic markers and novel therapeutic targets. The regulation of cell adhesion complex proteins, and specifically E-cadherin, during disease processes has become the focus of intensive research. Investigations into reduced E-cadherin function in cancer have included hereditary mutational analysis, promoter hypermethylation analysis, transcriptional repression analysis and posttranslational modification studies. Posttranslational truncation of E-cadherin and subsequent disruption of cell adhesion appear to facilitate tumour dissemination. Furthermore, the resulting increase in cytoplasmic ␤ -catenin levels can enhance proliferation via the wnt signalling pathway [Korinek et al., 1997] . In this paper, we review the evidence that posttranslational truncation of E-cadherin is associated with tumour progression.
Posttranslational Truncation of E-Cadherin
Posttranslational modification of E-cadherin occurs during normal maturation of the protein. E-cadherin is synthesized as a 135-kDa inactive precursor protein [Peyrieras et al., 1983] . Maturation in the Golgi network involves proteolytic cleavage of pro-E-cadherin near the Nterminus at a specific recognition sequence [Arg/Lys-(X) n -Lys/Arg-Arg] (n = 0, 2, 4 or 6) by a subtilisin-like proprotein convertase ( fig. 1 a) . Once processed the functional mature E-cadherin protein is translocated to the cell membrane ( fig. 1 b) . While pro-E-cadherin can integrate into the cell membrane, it lacks adhesive ability, indicating that proteolytic processing is essential for the adhesive function of E-cadherin [Ozawa and Kemler, 1990] .
The first alternative form of E-cadherin described was a soluble 80-kDa protein, gp80, which was subsequently found to be soluble E-cadherin (sE-cad) ( fig. 1 c) . This protein is constitutively released into culture medium by MCF-7 human mammary carcinoma cells. sE-cad-containing conditioned medium inhibits aggregation of cultured epithelial cells and prevents cell compaction at the eight-cell stage of mouse embryogenesis [Damsky et al., 1983; Wheelock et al., 1987] . This truncated form of Ecadherin may function as a pseudo-ligand that blocks normal E-cadherin interactions, resulting in reduced adhesion. Elevated levels of sE-cad have also been detected in vivo in serum and urine of cancer patients, suggesting a link between E-cadherin truncation and tumourigenesis [Katayama et al., 1994; Banks et al., 1995; Griffiths et al., 1996; Gofuku et al., 1998; Protheroe et al., 1999; Rashid et al., 2001] .
Studies involving the matrix metalloprotease (MMP) stromelysin-1 (SL-1) indicate that sE-cad occurs as a result of protease-mediated truncation of E-cadherin [Lochter et al., 1997] . Lochter et al. detected soluble 95-and 80-kDa fragments that react with the ECCD-2 anti-E-cadherin antibody following overexpression of SL-1 in SCp2 mammary epithelial cells. Appearance of these fragments was inhibited by the GM6001 general MMP inhibitor. A 40-kDa ECCD-2-reactive fragment is also detected regardless of SL-1 presence. SL-1 expression induces cell scattering, an invasive phenotype and expression of a mesenchymal-like cytoskeleton with decreased cytokeratin and increased vimentin expression. While increased keratinocyte growth factor mRNA expression also occurs, recombinant keratinocyte growth factor alone is not enough to induce the phenotypic changes induced by SL-1. The MMP family of proteases regulates ductal morphogenesis, apoptosis and neoplastic progression in mammary epithelial cells [Lochter et al., 1997] . MMPs were traditionally thought to contribute to tumourigenesis solely via degradation of the extracellular matrix, thereby facilitating invasion during tumour progression. It now appears, however, that SL-1 activity has multiple consequences for epithelial cells and may play a direct role in tumour cell invasion and cancer progression.
The role of MMPs in sE-cad production is further substantiated by Noe et al. [2000] who demonstrate increased release of sE-cad by MDCK kidney epithelial cells following treatment with recombinant SL-1, or matrilysin, another MMP. The presence of the MMP inhibitor TIMP-2 reduces levels of sE-cad in MCF-7 breast carcinoma cells. Purified and immobilized E-cadherin protein from both MDCK and MCF-7 cells are directly cleaved by SL-1 and matrilysin to yield 80-and 40-kDa fragments. Conditioned medium from SL-1-and matrilysin-treated MDCK cells inhibits cell aggregation and induces a more invasive phenotype. Thus the MMPs SL-1 and matrilysin can directly cleave E-cadherin to produce a soluble fragment that can increase invasion and inhibit cell aggregation in an autocrine manner.
Another protease implicated in the creation of truncated E-cadherin during tumour progression is calpain, a ubiquitously expressed protease involved in cell cycle regulation, signal transduction, cell migration and apoptosis. Calpain induces the accumulation of a 100-kDa Ecadherin fragment (E-cad 100 ) in prostate LNCaP and breast MCF-7 epithelial cells ( fig. 1 d) [Rios-Doria et al., 2003] . Both -and m-calpain directly cleave E-cadherin to produce E-cad 100 . The calpain cleavage site is located upstream of the ␤ -and ␥ -catenin binding domains of the cytoplasmic tail of E-cadherin, and amino acid residues 782-787 are essential for calpain-mediated cleavage. m-Calpain expression is increased in localized and metastatic prostate cancer compared to benign prostate tumours and correlates with the appearance of E-cad 100 in the tumour aspect of prostate tissue when compared to normal tissue. E-cad 100 was also observed in all matched prostate metastases. Therefore, calpain expression is associated with prostate tumourigenesis, and calpain-mediated cleavage of E-cadherin is correlated with inactivation, specifically in prostate cancer and metastases [Rashid et al., 2001; Rios-Doria et al., 2003 ]. Calpain-mediated release of the catenin binding domain of E-cadherin may support the malignant transformation of these cells and contribute to destabilizing the adhesive function of E-cadherin.
Although proteolytic cleavage of E-cadherin has been associated with tumour progression, the mechanisms by which alternative forms of E-cadherin may facilitate carcinogenesis remain unclear. Hepatocyte growth factor/ scatter factor (HGF/SF) is a multifunctional cytokine that induces cell scattering in epithelial and cancer cells. HGF/SF treatment of LNCaPFGC prostate cancer cells increases 80-kDa sE-cad secretion, reduces ␤ -catenin binding capacity and increases cell scattering and invasive ability [Davies et al., 2001] . Inhibition of matrilysin prior to HGF/SF treatment prevents sE-cad production. This suggests that generation of an invasive phenotype in these cells in response to HGF/SF treatment occurs via matrilysin activation. A histidine-alanine-valine (HAV) amino acid sequence, crucial for homophilic cadherin interactions, is located in the extracellular domain of E-cadherin [Noe et al., 1999] . This sequence is highly conserved among cadherins and is therefore considered to have an important and specific function. Peptide constructs containing these HAV sequences induce epithelial cell invasion and reduce cell aggregation in epithelial cell lines in a cadherin-type and species-specific manner [Noe et al., 1999] . sE-cad may thus act in an autocrine manner to induce and support an invasive phenotype in cancer cells. HAV peptides increase expression of MMP-2, MMP-9 and MT1-MMP and enhance the invasive ability of 16HBE14o-bronchial epithelial cells [Nawrocki-Raby et al., 2003] . The increase in invasive potential is MMP dependent as indicated by its abrogation in the presence of MMP inhibitor. The HAV peptide which is conserved in all cadherins may therefore play a role in MMP induction and subsequent cell invasion via the release of sE-cad from tumour cells.
These associations between E-cadherin truncations and cancer progression have stimulated exploration into the potential utility of truncated E-cadherin as a biomarker for cancer progression in the prostate . Serum and urine levels of sE-cad, along with increased levels of MMPs, are potential indicators of metastatic progression in prostate cancer, and high levels of sE-cad may be an indicator of high recurrence levels of bladder cancer [Griffiths et al., 1996; Kuefer et al., 2003] .
In summary, disruption of stable cell-cell adhesion is a fundamental process that facilitates proliferation, cell motility and tumour dissemination, and usually involves the loss of function of a number of proteins. We are currently investigating the role of E-cadherin inactivation via truncation during tumour progression . Signalling proteases such as stromelysin, matrilysin, calpain and HGF/SF appear to be involved in this process, although precise mechanisms remain to be elucidated. The existence of truncated forms of E-cadherin and resulting effects on integrity of adherens junctions is an important consideration if E-cadherin is to be used as an indicator of tumour status.
